1. Volume 64, Pages S131-S136 (November 2003)
The impact of calcimimetics on mineral metabolism and secondary hyperparathyroidism in end-stage renal disease 
Geoffrey A. Block 
Kidney International 
Volume 64, Pages S131-S136 (November 2003)
DOI: /j s87.20.x
Copyright © 2003 International Society of Nephrology Terms and Conditions

2. Figure 1
Mechanisms underlying secondary hyperparathyroidism (SHPT). Calcium is the key regulator of parathyroid hormone (PTH) secretion.
Kidney International  , S131-S136DOI: ( /j s87.20.x)
Copyright © 2003 International Society of Nephrology Terms and Conditions

3. Figure 2
Contrasting effects of vitamin D and calcimimetic compounds on the daily pattern of parathyroid hormone (PTH).
Kidney International  , S131-S136DOI: ( /j s87.20.x)
Copyright © 2003 International Society of Nephrology Terms and Conditions

4. Figure 3
Effect of calcimimetic on the sigmoidal Ca2+-parathyroid hormone (PTH) relationship. Calcimimetics result in a leftward shift of the set point, thereby resulting in greater PTH suppression at any level of ionized calcium.
Kidney International  , S131-S136DOI: ( /j s87.20.x)
Copyright © 2003 International Society of Nephrology Terms and Conditions

5. Figure 4
Shown is parathyroid hormone (PTH) suppression achieved with cinacalcet HCl during a 2-year trial in which patients were randomized to placebo or cinacalcet (up to 50mg/day or up to 100mg/day) during the first year and subsequently rolled over into open label therapy with cinacalcet at doses up to 180mg/day.
Kidney International  , S131-S136DOI: ( /j s87.20.x)
Copyright © 2003 International Society of Nephrology Terms and Conditions